# Liraglutide Effects on Epicardial Fat Inflammatory Genes

> **NCT03260881** · PHASE4 · COMPLETED · sponsor: **University of Miami** · enrollment: 38 (actual)

## Conditions studied

- Type2 Diabetes
- Coronary Artery Disease

## Interventions

- **DRUG:** Liraglutide Pen Injector [Victoza]
- **DRUG:** matching liraglutide-placebo pre-filled pens

## Key facts

- **NCT ID:** NCT03260881
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2024-09-05
- **Final completion:** 2024-09-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03260881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03260881, "Liraglutide Effects on Epicardial Fat Inflammatory Genes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03260881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*